208 related articles for article (PubMed ID: 20924111)
1. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.
Teng MW; Ngiow SF; von Scheidt B; McLaughlin N; Sparwasser T; Smyth MJ
Cancer Res; 2010 Oct; 70(20):7800-9. PubMed ID: 20924111
[TBL] [Abstract][Full Text] [Related]
2. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
3. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors.
Li X; Kostareli E; Suffner J; Garbi N; Hämmerling GJ
Eur J Immunol; 2010 Dec; 40(12):3325-35. PubMed ID: 21072887
[TBL] [Abstract][Full Text] [Related]
4. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
5. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.
Lahl K; Loddenkemper C; Drouin C; Freyer J; Arnason J; Eberl G; Hamann A; Wagner H; Huehn J; Sparwasser T
J Exp Med; 2007 Jan; 204(1):57-63. PubMed ID: 17200412
[TBL] [Abstract][Full Text] [Related]
6. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
7. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
[TBL] [Abstract][Full Text] [Related]
8. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice.
Suffner J; Hochweller K; Kühnle MC; Li X; Kroczek RA; Garbi N; Hämmerling GJ
J Immunol; 2010 Feb; 184(4):1810-20. PubMed ID: 20083650
[TBL] [Abstract][Full Text] [Related]
10. Limitations of Foxp3(+) Treg depletion following viral infection in DEREG mice.
Christiaansen AF; Boggiatto PM; Varga SM
J Immunol Methods; 2014 Apr; 406():58-65. PubMed ID: 24642426
[TBL] [Abstract][Full Text] [Related]
11. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
12. Nonfunctional regulatory T cells and defective control of Th2 cytokine production in natural scurfy mutant mice.
Lahl K; Mayer CT; Bopp T; Huehn J; Loddenkemper C; Eberl G; Wirnsberger G; Dornmair K; Geffers R; Schmitt E; Buer J; Sparwasser T
J Immunol; 2009 Nov; 183(9):5662-72. PubMed ID: 19812199
[TBL] [Abstract][Full Text] [Related]
13. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
14. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E
Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720
[TBL] [Abstract][Full Text] [Related]
15. In vivo depletion of FoxP3+ Tregs using the DEREG mouse model.
Lahl K; Sparwasser T
Methods Mol Biol; 2011; 707():157-72. PubMed ID: 21287334
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APC
Akeus P; Szeponik L; Ahlmanner F; Sundström P; Alsén S; Gustavsson B; Sparwasser T; Raghavan S; Quiding-Järbrink M
Cancer Immunol Immunother; 2018 Jul; 67(7):1067-1077. PubMed ID: 29671006
[TBL] [Abstract][Full Text] [Related]
17. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
Vocanson M; Rozieres A; Hennino A; Poyet G; Gaillard V; Renaudineau S; Achachi A; Benetiere J; Kaiserlian D; Dubois B; Nicolas JF
J Allergy Clin Immunol; 2010 Aug; 126(2):280-9, 289.e1-7. PubMed ID: 20624644
[TBL] [Abstract][Full Text] [Related]
18. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
[TBL] [Abstract][Full Text] [Related]
19. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
